The FDA dealt another blow to Inspire Pharmaceuticals Inc. with a second approvable letter for its investigational dry eye drug, diquafosol, shaving a third off the company's stock value Friday. (BioWorld Today)
The FDA dealt another blow to Inspire Pharmaceuticals Inc. with a second approvable letter for its investigational dry eye drug, diquafosol, shaving a third off the company's stock value Friday. (BioWorld Today)
XenoPort Inc. could receive more than $85 million after agreeing to out-license Asian rights to its lead product candidate, XP13512, to Astellas Pharma Inc. (BioWorld Today)
XenoPort Inc. could receive more than $85 million after agreeing to out-license Asian rights to its lead product candidate, XP13512, to Astellas Pharma Inc. (BioWorld Today)
The holiday season is coming early to BioCryst Pharmaceuticals Inc., which could earn more than half a billion dollars per terms of a just-announced licensing deal with F. Hoffmann-La Roche Ltd. (BioWorld Today)
The holiday season is coming early to BioCryst Pharmaceuticals Inc., which could earn more than half a billion dollars per terms of a just-announced licensing deal with F. Hoffmann-La Roche Ltd. (BioWorld Today)
